Thursday, October 26 2023 | 4:00 – 5:00 PM CET
What are the challenges posed by rare diseases and how can we address the essential needs of patients while navigating these conditions across all clinical phases? By leveraging the power of Quality of Life (QoL) data, personalized treatment algorithms and Real-World Evidence, we can build a comprehensive approach to managing these conditions effectively.
In our next Climedo Connect on October 26, Domenico Merante and Henrik Schou of CSL Vifor will present their insights and expertise on how advancements in technology, data analysis and evidence-based strategies can reshape the landscape of rare disease management and close important knowledge gaps. They will share practical examples of how the integration of these elements can offer innovative solutions to the challenges faced by both rare disease patients and healthcare professionals. Join us as we discuss:
- Rare disease challenges, patient needs and opportunities
- The importance of QoL data, treatment algorithms and RWE for patient outcomes
- Best practices in rare disease data management during clinical development and in the post-approval phase
Meet Our Speakers
Laura Dosch (Host)
As an Account Manager at Climedo, Laura accompanies customers from the medical device and pharmaceutical sectors on their way to the successful digitalization of clinical trials. She advises companies on the use of Climedo's modular, decentralized and patient-centric solutions for EDC, eCOA/ePRO, eConsent and the integration of wearables and Telemedicine to bring the best treatments to patients.
Opinions are her own and don’t represent Climedo as a company.
Global Clinical Development TA Lead Nephrology and Orphan/Rare Disease Area
Global Head Evidence Generation
As a Health Economist and Mathematician/Statistician, Henrik is a seasoned Global Pharma Executive. His career spans Novo Nordisk, Sanofi and CSL Vifor, excelling in RD, Regulatory, Medical Affairs, Pricing and Market Access. Currently Head of Evidence Generation at CSL Vifor, he chairs the Phase Four Research Board and is integral to the Senior Leadership Team.
Opinions are his own and don’t represent CSL Vifor as a company.
What's on the Agenda?
- Intro (Laura Dosch)
- Challenges and opportunities in clinical development and post-approval phases for rare diseases
- Case study in ANCA-Associated Vasculitis and a discussion on gaps in QoL data and outcomes (Domenico Merante)
- Real-World Evidence / Real-World Data (Phase IV) with historical examples and personalized treatments (Henrik Schou)
- Where are we today and final remarks (Domenico Merante and Henrik Schou)
- Discussion and networking (all)
- Wrap-up (Laura Dosch)
A transformative perspective on leveraging technology and evidence-based strategies to revolutionize rare disease management.
Practical examples from the fields of rare and life-threatening diseases, based on historical examples.
NETWORKING & DISCUSSION
Talk to other industry professionals and find out how they are tackling challenges similar to yours.
The Digital Platform for Innovative Clinical Trial Execution.
Climedo offers a digital health platform for hybrid clinical trials and observational studies. Its easy-to-use, modular and secure solutions for data management include electronic data capture (EDC), ePRO, eCOA, and Telemedicine.
This enables pharma and medtech companies to validate their medical innovations more efficiently in the post-market phase and to capture data in decentralized, real-world settings. As a result, they accelerate studies, save costs, and improve data flow and quality, while fostering innovative trial designs.
By connecting all stakeholders (industry partners, study sites, physicians and patients) in one cloud-based system, Climedo is revolutionizing clinical research and making trials more accessible and patient centric.